Peijia Medical's TaurusTrio Valve Receives Pioneering NMPA Approval, Transforming Aortic Regurgitation Treatment in China

Peijia Medical's New Era in Aortic Regurgitation Treatment

Peijia Medical (9996.HK), a prominent player in the burgeoning markets of transcatheter valves and neurovascular interventions, has recently announced a groundbreaking advancement in cardiac care. The company has received approval from the National Medical Products Administration (NMPA) of China for its TaurusTrio Transcatheter Aortic Valve (TAV) system, marking a pivotal moment for patients suffering from aortic regurgitation (AR).

Unveiled on December 11, 2025, the TaurusTrio system represents a significant evolution in the treatment of symptomatic, severe aortic regurgitation. This condition poses intricate challenges as it often lacks the calcified structures necessary for standard valve anchoring. Dr. Yi Zhang, Chairman and CEO of Peijia Medical, emphasized that for many patients ineligible for surgical interventions, the lack of suitable treatment options has constituted a considerable unmet clinical need.

The innovative design of the TaurusTrio system incorporates JenaValve Technology, Inc.'s proprietary locator technology, which provides a unique solution to the anchoring problem faced by patients with aortic regurgitation. This technology enables a secure attachment by engaging the native aortic leaflets, even in cases devoid of calcium. Such mechanisms ensure optimal valve positioning and alignment, a crucial factor in ensuring procedural success and patient safety.

Early clinical results from the TaurusTrio ALTER-AR study have been exceptionally promising. With a technical success rate of 99.1%, the system recorded zero all-cause mortality within 30 days post-procedure, and only 2.6% mortality rate at the one-year mark. Remarkably, over 90% of participants observed marked improvements in cardiac function, progressing to NYHA class I/II status at six months. Additionally, the incidence of moderate or greater paravalvular leak was observed to be non-existent one year post-implantation, further contributing to the early validation of the device's long-term safety and efficacy.

The collaboration between Peijia Medical and JenaValve has laid the groundwork for this transformative product. JenaValve CEO, John Kilcoyne, expressed enthusiasm over the approval, highlighting the hard work that has culminated in the successful introduction of the TaurusTrio system into the Chinese market. He reiterated the importance of addressing the needs of patients suffering from AR, who have historically been underserved in terms of viable treatment options.

This approval not only signifies a noteworthy achievement for Peijia Medical, but it also resonates with its strategy aimed at advancing structural heart disease innovation. By bridging global expertise and local execution, the company is poised to enhance the landscape of interventional treatments available in China.

As Peijia Medical continues on its commitment to transforming cardiac care, the TaurusTrio system stands as a testament to the company’s innovation and dedication to patient welfare. Aiming to build a robust local innovation ecosystem, Peijia Medical is collaborating with global partners to introduce cutting-edge technologies tailored to meet the unique patient needs within the region.

In summary, the TaurusTrio's NMPA approval signifies more than just regulatory acknowledgment; it heralds a new phase in aortic regurgitation treatment, promising improved survival rates and quality of life for patients in China. With the roll-out of this technology, we are witnessing a pivotal moment in cardiovascular care that emphasizes precision, minimal invasiveness, and patient-centered solutions.

About Peijia Medical
Founded in 2012 and headquartered in Suzhou, China, Peijia Medical is dedicated to addressing the growing needs of the interventional procedural medical device market. With a portfolio that includes several TAVR systems and numerous neurointerventional devices, Peijia Medical continues to push the boundaries of innovation in structural heart and neurovascular diseases. For more information, please visit Peijia Medical.